Cyclerion Therapeutics Stock Today
| CYCN Stock | USD 2.93 0.10 3.53% |
Performance4 of 100
| Odds Of DistressOver 79
|
Cyclerion Therapeutics is selling at 2.93 as of the 23rd of September 2024; that is 3.53 percent increase since the beginning of the trading day. The stock's open price was 2.83. Cyclerion Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Cyclerion Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of August 2024 and ending today, the 23rd of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 2019 | Category Healthcare | Classification Health Care |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. The company has 2.52 M outstanding shares of which 13.07 K shares are currently shorted by private and institutional investors with about 3.23 trading days to cover. More on Cyclerion Therapeutics
Moving against Cyclerion Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cyclerion Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Regina Graul | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCyclerion Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cyclerion Therapeutics' financial leverage. It provides some insight into what part of Cyclerion Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cyclerion Therapeutics (CYCN) is traded on NASDAQ Exchange in USA. It is located in 245 First Street, Riverview II, Cambridge, MA, United States, 02142 and employs 1 people. Cyclerion Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.37 M. Cyclerion Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.52 M outstanding shares of which 13.07 K shares are currently shorted by private and institutional investors with about 3.23 trading days to cover.
Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Check Cyclerion Therapeutics Probability Of Bankruptcy
Ownership AllocationCyclerion Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Cyclerion Ownership Details
Cyclerion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 649 | |
| Group One Trading, Lp | 2024-06-30 | 540 | |
| Royal Bank Of Canada | 2024-06-30 | 416 | |
| Activest Wealth Management | 2024-06-30 | 100.0 | |
| Bank Of America Corp | 2024-06-30 | 16.0 | |
| Pnc Financial Services Group Inc | 2024-06-30 | 2.0 | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Farmers National Bank | 2024-06-30 | 0.0 | |
| Slate Path Capital Lp | 2024-06-30 | 357.9 K | |
| Mfn Partners Management, Lp | 2024-06-30 | 169.5 K |
Cyclerion Therapeutics Historical Income Statement
Cyclerion Stock Against Markets
Cyclerion Therapeutics Corporate Management
| Todd Milne | Senior Innovation | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Jessica Rennekamp | Associate Communications | Profile | |
| Christopher Winrow | Sr Lead | Profile | |
| Jennifer Chickering | Director Strategy | Profile | |
| Rhonda Chicko | Chief Officer | Profile |
Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.